September 11, 2008 - Advanced image-processing and 3D visualization solutions provider TeraRecon Inc. today released new innovations in its flagship Aquarius iNtuition platform at the American Society of Nuclear Cardiology (ASNC) Annual Meeting in Boston, Sept. 11-14, 2008.

September 11, 2008 - Royal Philips Electronics today said it has signed a memorandum of understanding (MOU) setting out a long-term research partnership with the University Medical Center (UMC) Utrecht, the Netherlands’ biggest university hospital, to develop new solutions for the diagnosis, monitoring and treatment of several major diseases.

September 11, 2008 -Cook Medical has completed enrollment in the first international clinical trial of a first-of-its-kind drug-eluting stent designed to treat arterial blockages outside the coronary arteries.

September 11, 2008 - Good Samaritan Hospital was among the first in the nation to implant a TELIGEN implantable cardioverter defibrillator (ICD) made by Boston Scientific.

September 11, 2008 - Mennen Medical recently released a new cath lab hemodynamic monitoring system, the Horizon XVu, which is embedded with an ultra modern interface and analysis system, includes network ability and efficient workflow connectivity as part of Mennen Medical’s total IT solution.

September 11, 2008 - The American College of Cardiology (ACC) has certified LUMEDX an ACC-NCDR CARE Registry software vendor, making LUMEDX the first vendor certified for carotid stent procedures.

LUMEDX's Export to CARE Registry solution is the latest in a suite of software applications developed to address the growing need for impeccable, accessible vascular data, streamlined clinical workflows and superior data management.

TeraRecon Inc. released new innovations in its flagship Aquarius iNtuition client-server to empower nuclear cardiologists to improve efficiency within their cardiac imaging portfolio.

September, 10, 2008 - Members of the Venous Disease Coalition (VDC) and the Office of the Surgeon General will unite to urge immediate action in the fight against deadly blood clots known as deep vein thrombosis (DVT) on Sept. 15. at the VDC Annual Meeting at The Grand Hyatt Hotel, Washington, D.C.

September 10, 2008 - CardioVascular BioTherapeutics Inc. announced yesterday that the first U.S. site is open for patient enrollment in the company’s Phase II clinical trial for the treatment of severe coronary heart disease.
CVBT anticipates announcing the opening of additional sites for enrollment in the coming weeks.

The FDA recently cleared Boston Scientific Corp.’s PROMUS Everolimus-Eluting Coronary Stent System.

Boston Scientific said the PROMUS Stent is highly deliverable, made from cobalt chromium, which allows for thinner struts without sacrificing strength or visibility.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now